Skye Bioscience Inc (SKYE)

[Paulieme]

March 15, 2017 at 1:16 pm-- Cannabis Panels Demonstrate Growing Appeal to Institutional Investors! The 29th annual ROTH Conference, which is sponsored by Roth Capital Partners. The panel on the 14th, which was moderated by Ted Roth, President of ROTH Capital, and also included Christopher Barry of Dorsey & Whitney, Scott Ginsburg of MM Acquisition Co, LLC, Alan Gold of Innovative Industrial Properties (NYSE: IIPR) and Dr. Brian Murphy of Nemus Bioscience (OTC: NMUS). Each of the panelists gave a brief summary of their company’s involvement in the industry before Roth asked a few questions and then the audience participated.DR.Murphy, who serves as CEO and Chief Medical Officer(OTC NMUS), is working with Albany Molecular Research (NASDAQ: AMRI) for synthetic cannabinoid production and with Teewinot Life Sciences for biosynthetic cannabinoid production. The company also works with the University of Mississippi to develop IP and employs a variety of drug delivery devices. Its areas of focus include glaucoma, MRSA, chemotherapy-induced nausea and vomiting (CINV) and chemotherapy-induced peripheral neuropathy (CIPN). Murphy, who has been involved previously with three biotech startups, made the case for why he expects the industry will shift towards synthetics over time. https://www.newcannabisventures.com/roth-conference-cannabis-panels-demonstrate-growing-appeal-to-institutional-investors/